Search

Your search keyword '"Babu, Tara M."' showing total 45 results

Search Constraints

Start Over You searched for: Author "Babu, Tara M." Remove constraint Author: "Babu, Tara M."
45 results on '"Babu, Tara M."'

Search Results

1. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

2. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants

5. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years

6. Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine

7. 2395. An Interim Report of the Safety, Reactogenicity, and Immunogenicity of a Self-amplifying mRNA (samRNA) COVID-19 Vaccine GRT-R910 as a Booster in Healthy Adults

11. Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

12. CASCADIA: a prospective community-based study protocol for assessing SARS-CoV-2 vaccine effectiveness in children and adults using a remote nasal swab collection and web-based survey design

13. Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

14. Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.

15. Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

16. Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial

17. Genital Herpes Simplex Virus Type 2 Suppression With Valacyclovir Is Not Associated With Changes in Nugent Score or Absolute Abundance of Key Vaginal Bacteria

18. Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial

19. CASCADIA: A prospective community-based study protocol for assessing SARS-CoV-2 vaccine effectiveness in children and adults utilizing a remote nasal swab collection and web-based survey design

20. 1948. Evaluation of a heterologous booster vaccine regimen: Pfizer-BioNTech BNT162b2 mRNA booster vaccine following priming with Novavax NVX-CoV2373

21. 2202. Influenza Surveillance of Families in an Observational Household Study 2019-2021

23. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses

24. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

25. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

26. Homologous and Heterologous Covid-19 Booster Vaccinations

29. Probable Donor-Derived Human Adenovirus Type 34 Infection in 2 Kidney Transplant Recipients From the Same Donor.

30. CNS Melioidosis in a Traveler Returning from Cabo, Mexico

32. Colaboradores

34. Contributors

35. Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.

36. Invasive Aspergillus infections in hospitalized patients with chronic lung disease

38. Mycobacterium avium-complex pericarditis: a case of unmasking immune reconstitution inflammatory syndrome.

39. Invasive Aspergillus infections in hospitalized patients with chronic lung disease.

40. Next-Generation SARS-CoV-2 Vaccine Formulations and Alternative Routes of Administration.

41. Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.

42. Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.

43. Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.

44. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses.

45. Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report.

Catalog

Books, media, physical & digital resources